Analysis of Jacobio Out-licensed KRAS G12C Inhibitor Glecirasib and SHP2 Inhibitor JAB-3312 to Allist in China - aVenture Research
PRNewswire
Jacobio Out-licensed KRAS G12C Inhibitor Glecirasib and SHP2 Inhibitor JAB-3312 to Allist in China
Jacobio Pharma granted the China rights (mainland China, Hong Kong, Macau, Taiwan) of KRAS G12C inhibitor glecirasib and SHP2 inhibitor JAB-3312 to Shanghai Allist Pharmaceuticals. Jacobio receives around RMB200 million near term, including an RMB150 million upfront payment, plus potential milestone payments up to RMB700 million and tiered double-digit royalties, with JAB-3312 royalties up to 20%. Allist takes responsibility for commercialization in China and subsequent China clinical development costs, marking Jacobio's entry into the commercialization stage.
An analysis reads this article and its sources, then explains what happened, who is involved, and what it means, quoting a source for each claim. Once written, every reader sees it here.
Analysis requires a paid plan or prepaid credits and uses your company research allowance.